Subjects will be stratified by sex and then randomly assigned to active progesterone (PRO) or placebo (PBO).
Telephone screening and visit invitation leads to the consent process and in-person screening including medical-psychiatric evaluation for inclusion/exclusion, then randomization and medication induction, stable medication with medication reduction and final evaluation for secondary outcomes.
